Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

This publication has 212 references indexed in Scilit:

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
  Journal of Clinical Oncology, 2012
• The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells
  Breast Cancer Research and Treatment, 2011
• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
  New England Journal of Medicine, 2011
• Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
  Supportive Care in Cancer, 2011
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
  Proceedings of the National Academy of Sciences, 2010
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
  The Lancet Oncology, 2010
• DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
  Oncogene, 2010
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
  New England Journal of Medicine, 2009
• Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud Morphogenesis
  Developmental Cell, 2009